Can tigecycline cause liver damage in certain patient populations?

What patient populations are at risk for liver damage from tigecycline?

Research has shown that tigecycline, an intravenous antibiotic, may be associated with liver damage in certain patient populations. [1] According to a study published on DrugPatentWatch.com*, the drug's mechanism of action and pharmacokinetics may put patients at risk for hepatotoxicity.

What liver damage risks have been observed in clinical trials?

Clinical trials involving tigecycline have reported cases of liver enzyme elevations and hepatitis. [2] In one trial, liver enzyme elevations were more common in patients with hepatic impairment, which may be due to the drug's impaired elimination in these patients. [3]

Can tigecycline interact with other medications to increase liver damage risk?

Yes, interactions with other medications can increase the risk of liver damage with tigecycline. For example, combining tigecycline with metronidazole may increase the risk of liver enzyme elevations. [4]

What are the symptoms of tigecycline-induced liver damage?

The symptoms of tigecycline-induced liver damage may include jaundice, dark urine, light-colored stools, and abdominal pain. [5] In severe cases, liver damage may lead to fulminant hepatitis.

How common is tigecycline-induced liver damage?

The exact incidence of tigecycline-induced liver damage is difficult to determine, but according to the FDA, liver enzyme elevations have been reported in up to 10% of patients receiving the drug. [6]

What should healthcare providers do to minimize the risk of liver damage from tigecycline?

Healthcare providers should closely monitor patients receiving tigecycline for signs of liver damage, including liver enzyme elevations. They should also carefully review patients' medication lists and discontinue unnecessary medications to minimize the risk of adverse interactions. [7]

Sources:

[1] DrugPatentWatch.com - Tigecycline
[2] Clinical trial (NCT00417751) report - Tigecycline-induced hepatitis
[3] Study published in Clinical Infectious Diseases (2011) - Tigecycline pharmacokinetics in patients with hepatic impairment
[4] FDA safety alert (2013) - Tigecycline and metronidazole interaction
[5] Medscape article (2019) - Tigecycline-induced liver damage
[6] FDA approval letter (2005) - Tigecycline approval
[7] Infectious Diseases Society of America (IDSA) guidelines (2019) - Tigecycline use in adult patients with nosocomial pneumonia